Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
Richard Furie(Hofstra University), Raj Tummala(Hofstra University), Edward M Vital(University of Leeds), Theresa Lawrence Ford(Georgia Urology), Eric F. Morand(Novartis (Switzerland)), Ian N Bruce(University of Manchester), Philip Z. Brohawn(Hofstra University), Anna Berglind(Hofstra University), Ramesh K. Gupta(Baptist Memorial Hospital), Mittermayer B. Santiago(Fundação Bahiana de Infectologia), Kenneth Kalunian(University of California, San Diego), Susan Manzi(Allegheny Health Network), Falk Hiepe(Leibniz Association)
Cited by 478
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726